P2Y11 Antagonist B7508: Selective GPCR Inhibitor for Cell Signaling Research

Executive Summary: The P2Y11 antagonist (B7508) is a validated, selective inhibitor of the P2Y11 G protein-coupled receptor (GPCR) used in cell signaling studies (APExBIO). Its molecular weight is 986.84 Da, and it is highly water-soluble at concentrations under 19.74 mg/ml. Peer-reviewed evidence demonstrates that B7508 (NF340) reverses QPRT-induced breast cancer cell invasiveness by blocking purinergic signaling, as shown in human cell line models (Liu et al., 2021). The compound is stable at -20°C and should be used promptly after solution preparation for optimal activity. B7508 is not for diagnostic or medical use but is pivotal in mechanistic research on inflammation, immune modulation, and cancer biology.

Biological Rationale

The P2Y11 receptor is a GPCR involved in purinergic signaling, mediating various physiological and pathophysiological processes, including immune cell activation, cytokine release, and inflammation modulation (see GPCR signaling review). Overexpression or aberrant activation of P2Y11 has been implicated in disease states such as cancer progression and neuroinflammation (Liu et al., 2021). In breast cancer, purinergic signaling via the P2Y11 pathway facilitates myosin light chain phosphorylation, enhancing cell motility and invasiveness. Targeting this receptor allows researchers to dissect the molecular contributions of GPCRs to inflammation and tumor biology, supporting the rationale for using specific antagonists like B7508 in mechanistic studies.

Mechanism of Action of P2Y11 antagonist

B7508 acts as a competitive antagonist at the P2Y11 receptor, inhibiting signal transduction initiated by extracellular nucleotides such as ATP. Upon binding, B7508 blocks Gs-protein-mediated cAMP elevation and downstream PLC activation, ultimately disrupting pathways that regulate cytoskeletal dynamics and gene expression (see mechanism overview). In breast cancer cell models, B7508 specifically inhibits QPRT-induced phosphorylation of myosin light chain—a key event in tumor cell migration and invasion. This effect is distinct from other GPCR antagonists due to B7508's selectivity for P2Y11, minimizing off-target impacts on related P2Y subtypes (Liu et al., 2021).

Evidence & Benchmarks

• B7508 (NF340) reversed QPRT-induced migratory and invasive phenotypes in human breast cancer cell lines at 37°C in 5% CO₂ cultures (Liu et al., 2021).
• B7508 blocked myosin light chain phosphorylation downstream of the P2Y11 receptor, as quantified by immunoblotting in MDA-MB-231 cells (Liu et al., 2021).
• The antagonist is water-soluble up to 19.74 mg/ml, allowing for high-concentration in vitro assays under standard cell culture conditions (APExBIO).
• Storage at -20°C and shipment on blue ice are required to maintain compound integrity for reproducible experimental results (APExBIO).
• B7508 selectively inhibits P2Y11, with minimal cross-reactivity to other P2Y subtypes under tested concentrations (≤10 μM) (see advanced applications).

Applications, Limits & Misconceptions

The P2Y11 antagonist B7508 is primarily used for:

• Dissecting purinergic signaling in immune cells, including T cell activation and cytokine profiling.
• Modeling inflammation and neuroinflammation in vitro, particularly in studies of cytokine release and glial function.
• Investigating cancer cell migration, invasion, and metastasis, especially in breast cancer models where QPRT-P2Y11 interactions are critical (see cancer research update).
• Studying autoimmune disease mechanisms where GPCR-mediated signaling is implicated.

B7508 should not be used for therapeutic, diagnostic, or in vivo clinical applications. Its selectivity profile means it may not block other purinergic (P2Y) receptors, and overuse or long-term storage in solution can degrade compound potency.

Common Pitfalls or Misconceptions

• B7508 is not suitable for clinical or diagnostic use; it is strictly for research purposes (APExBIO).
• Long-term storage of B7508 solutions reduces efficacy; use freshly prepared solutions for each experiment.
• Not all GPCRs are inhibited; B7508 is selective for P2Y11 and will not affect unrelated receptors.
• Effects observed in vitro may not translate to in vivo systems without additional pharmacokinetic validation.
• Dosing above solubility threshold (19.74 mg/ml) leads to precipitation and confounds data interpretation.

Workflow Integration & Parameters

Researchers should store B7508 at -20°C and protect from moisture and light. Reconstitute the beige solid in sterile water, not exceeding 19.74 mg/ml, and filter-sterilize if required for cell culture. Use freshly prepared solutions; avoid freeze-thaw cycles. Typical working concentrations range from 0.1–10 μM in cell culture assays, as established in breast cancer cell line studies (Liu et al., 2021). Shipping is performed on blue ice to preserve compound integrity. For optimized protocols and troubleshooting, see the internal guide on workflow integration for B7508, which expands on this workflow by providing troubleshooting tips.

Conclusion & Outlook

The P2Y11 antagonist B7508 from APExBIO is a rigorously validated tool for investigating GPCR-mediated cell signaling in immunology, oncology, and inflammation research. Recent studies confirm its selective inhibition of P2Y11, reversing QPRT-induced invasiveness in breast cancer cells (Liu et al., 2021). While highly effective in vitro, users must observe proper storage and handling to ensure reproducibility. For deeper mechanistic insights and translational applications, B7508 serves as a cornerstone in the expanding field of purinergic signaling research. This article clarifies and extends the mechanistic context found in recent molecular reviews by providing direct experimental benchmarks and product-specific protocols.